A Phase III, Double-Blind, Placebo-Controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as Add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist.

Trial Profile

A Phase III, Double-Blind, Placebo-Controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as Add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Safinamide (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms MOTION
  • Sponsors Newron Sweden AB
  • Most Recent Events

    • 21 Mar 2017 According to a Newron Pharmaceuticals media release, the Food and Drug Administration (FDA) has approved the use of Xadago (safinamide) for the treatment of Parkinsons disease as add-on therapy to levodopa/carbidopa, based on the data from MOTION and SETTLE studies.
    • 13 Nov 2015 According to a Zambon media release, Xadago (safinamide) was approved as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies for patients with Parkinson's disease in mid-to late-stage and motor fluctuations by Swissmedic on November 12, 2015.
    • 30 Sep 2015 According to a Newron Pharmaceuticals media release, late-cycle review meeting for the New Drug Application for safinamide has been completed with the U.S. Food and Drug Administration and the review time has been extended by the standard period of 3 months to review the late submission of additional financial disclosure forms for the MOTION and SETTLE clinical studies. This extends the PDUFA date to March 29, 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top